Cambridge Healthtech Institute’s 13th Annual

Clinical Biomarkers & Companion Diagnostics

Enabling Precision Medicine and Drug-Diagnostic Co-Development

March 12-13, 2025

The promise of precision medicine has been driven by the need to accurately predict patient response to therapy while ensuring drug efficacy and safety. Reducing costs and the time required for drug development are also driving forces in the use of biomarkers. Cambridge Healthtech Institute’s 13th Annual Clinical Biomarkers & Companion Diagnostics meeting will cover novel biomarkers and clinical trial applications, the role of biomarkers in clinical decision-making and drug-diagnostic co-development, and regulatory and policy updates.

Coverage will include, but is not limited to:

Precision medicine at big pharma
Biomarker-based clinical trials
Biomarkers for patient selection
Biomarkers to monitor response to therapy
Companion diagnostics
Regulatory and policy updates
Novel biomarkers and therapeutic areas

The deadline for priority consideration is September 13, 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: